SOLID TUMOURS:@0.084848:0.038601:0.266058:0.038601:0.266058:0.019343:0.084848:0.019343:0.011712:0.020438:0.010866:0.005315:0.017498:0.006515:0.010019:0.015405:0.021613:0.020438:0.015405:0.014276:0.011712
68:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
and  those  with  significant  comorbidity, :@0.084242:0.096166:0.480490:0.096166:0.480490:0.080410:0.084242:0.080410:0.013143:0.011738:0.013181:0.005330:0.007966:0.006523:0.011738:0.012604:0.007466:0.012508:0.005330:0.007963:0.015990:0.003848:0.006523:0.011738:0.005330:0.007963:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.005330:0.007963:0.012450:0.012604:0.018049:0.012604:0.005792:0.013123:0.003848:0.013181:0.003848:0.006523:0.010314:0.005330:0.005330
could be considered for non-surgical pro-:@0.084242:0.112557:0.475154:0.112557:0.475154:0.096801:0.084242:0.096801:0.012450:0.012604:0.011699:0.003848:0.013181:0.006071:0.013123:0.012508:0.006081:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005713:0.012508:0.013181:0.006071:0.006042:0.012604:0.005792:0.006065:0.011738:0.012604:0.011738:0.006388:0.007466:0.011699:0.005792:0.012950:0.003848:0.012450:0.013143:0.003848:0.006081:0.013123:0.005715:0.012604:0.006388
cedures  such  as cryoablation,  radiofre-:@0.084242:0.128947:0.475160:0.128947:0.475160:0.113192:0.084242:0.113192:0.012450:0.012508:0.013181:0.011699:0.005709:0.012508:0.007466:0.005330:0.006610:0.007466:0.011699:0.012450:0.011738:0.005330:0.006606:0.013143:0.007466:0.011950:0.012450:0.005792:0.010314:0.012604:0.013143:0.013123:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330:0.006602:0.005792:0.013143:0.013181:0.003848:0.012604:0.006042:0.005711:0.012508:0.006388
quency ablation (RFA), embolisation and :@0.084242:0.145338:0.480472:0.145338:0.480472:0.129582:0.084242:0.129582:0.013123:0.011699:0.012508:0.011738:0.012450:0.010314:0.007524:0.013143:0.013123:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.007524:0.007100:0.011680:0.008176:0.014239:0.007100:0.005330:0.007524:0.012508:0.018049:0.013123:0.012604:0.003848:0.003848:0.007466:0.013143:0.006523:0.003848:0.012604:0.011738:0.007535:0.013143:0.011738:0.013181:0.005330
palliative radiotherapy.:@0.084242:0.161729:0.301104:0.161729:0.301104:0.145973:0.084242:0.145973:0.013123:0.013143:0.003848:0.003848:0.003848:0.013143:0.006523:0.003848:0.010660:0.012508:0.005330:0.005792:0.013143:0.013181:0.003848:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
Attempts to improve control after surgery :@0.102426:0.178120:0.480528:0.178120:0.480528:0.162364:0.102426:0.162364:0.014047:0.006331:0.006331:0.012315:0.017857:0.012931:0.006331:0.007274:0.004580:0.006331:0.012411:0.004580:0.003656:0.017857:0.012931:0.005519:0.012411:0.010468:0.012315:0.004580:0.012257:0.012411:0.011545:0.006331:0.005519:0.012411:0.003656:0.004580:0.012950:0.005850:0.006331:0.012315:0.005600:0.004580:0.007274:0.011507:0.005613:0.012758:0.012315:0.005600:0.010316:0.005330
by adding adjuvant therapy is not stand-:@0.084242:0.194511:0.475152:0.194511:0.475152:0.178755:0.084242:0.178755:0.012931:0.010122:0.008005:0.012950:0.012989:0.012989:0.003656:0.011545:0.012758:0.008005:0.012950:0.012989:0.003714:0.011507:0.010468:0.012950:0.011545:0.006331:0.008005:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.008005:0.003656:0.007274:0.008005:0.011545:0.012411:0.006331:0.008005:0.007274:0.006331:0.012950:0.011545:0.012989:0.006388
ard care despite a positive trail (S-TRAC)  in :@0.084242:0.210902:0.480478:0.210865:0.480478:0.195109:0.084242:0.195146:0.012950:0.005482:0.012989:0.004934:0.012257:0.012950:0.005521:0.012315:0.004934:0.012989:0.012315:0.007274:0.012931:0.003656:0.006331:0.012315:0.004934:0.012950:0.004934:0.012931:0.012411:0.007274:0.003656:0.006331:0.003656:0.010468:0.012315:0.004936:0.006331:0.005600:0.012950:0.003656:0.003656:0.004934:0.006908:0.009390:0.006196:0.008005:0.011488:0.014047:0.015452:0.007100:0.005930:0.004934:0.003656:0.011736:0.695601
1:@0.448717:0.205246:0.454932:0.205246:0.454932:0.196061:0.448717:0.196061:0.006215
which observation was compared to one-:@0.084252:0.227256:0.475159:0.227256:0.475159:0.211500:0.084252:0.211500:0.015798:0.011545:0.003656:0.012257:0.011545:0.006312:0.012411:0.012931:0.007274:0.012315:0.005600:0.010468:0.012950:0.006331:0.003656:0.012411:0.011545:0.006312:0.015798:0.012950:0.007274:0.006312:0.012257:0.012411:0.017857:0.012931:0.012950:0.005521:0.012315:0.012989:0.006312:0.006331:0.012411:0.006312:0.012411:0.011545:0.012315:0.006388
year adjuvant sunitinib. (There was a statisti-:@0.084252:0.243647:0.475178:0.243647:0.475178:0.227891:0.084252:0.227891:0.010122:0.012315:0.012950:0.005600:0.004079:0.012950:0.012989:0.003714:0.011507:0.010468:0.012950:0.011545:0.006331:0.004079:0.007274:0.011507:0.011545:0.003656:0.006331:0.003656:0.011545:0.003656:0.012931:0.005138:0.004079:0.006908:0.008005:0.011545:0.012315:0.005521:0.012315:0.004079:0.015798:0.012950:0.007274:0.004079:0.012950:0.004079:0.007274:0.006331:0.012950:0.006331:0.003656:0.007274:0.006331:0.003656:0.006388
cal progression-free survival, but no overall :@0.084252:0.260038:0.480483:0.260038:0.480483:0.244282:0.084252:0.244282:0.012257:0.012950:0.003656:0.005907:0.012931:0.005519:0.012411:0.012758:0.005519:0.012315:0.007274:0.007274:0.003656:0.012411:0.011545:0.006196:0.005850:0.005521:0.012315:0.012315:0.005907:0.007274:0.011507:0.005600:0.010468:0.003656:0.010468:0.012950:0.003656:0.005138:0.005907:0.012931:0.011507:0.006331:0.005907:0.011545:0.012411:0.005907:0.012411:0.010468:0.012315:0.005600:0.012950:0.003656:0.003850:0.005330
survival benefit, and toxicity was such that :@0.084252:0.276429:0.480483:0.276429:0.480483:0.260673:0.084252:0.260673:0.007274:0.011507:0.005600:0.010468:0.003656:0.010468:0.012950:0.003656:0.006388:0.012931:0.012315:0.011545:0.012315:0.004589:0.004589:0.006331:0.005138:0.006388:0.012950:0.011545:0.012989:0.006387:0.006331:0.012411:0.009044:0.003656:0.012257:0.003656:0.006331:0.010122:0.006388:0.015798:0.012950:0.007274:0.006388:0.007274:0.011507:0.012257:0.011545:0.006387:0.006331:0.011545:0.012950:0.006519:0.005330
it is not generally recommended.):@0.084252:0.292820:0.393533:0.292820:0.393533:0.277064:0.084252:0.277064:0.003656:0.006331:0.005138:0.003656:0.007274:0.005138:0.011545:0.012411:0.006331:0.005138:0.012758:0.012315:0.011545:0.012315:0.005600:0.012950:0.003656:0.003656:0.010122:0.005138:0.005521:0.012315:0.012257:0.012411:0.017857:0.017857:0.012315:0.011545:0.012989:0.012315:0.012989:0.005138:0.007100
Advanced disease (stage IV):@0.084242:0.325888:0.386990:0.325888:0.386990:0.307867:0.084242:0.307867:0.015822:0.014111:0.011973:0.014111:0.012828:0.013683:0.013683:0.014111:0.005987:0.014111:0.005131:0.009407:0.013683:0.014111:0.009407:0.013683:0.005987:0.008125:0.009407:0.006414:0.014111:0.014111:0.013683:0.005987:0.005987:0.014966:0.008125
Almost all patients with metastatic renal :@0.084242:0.343420:0.480480:0.343420:0.480480:0.327664:0.084242:0.327664:0.014239:0.003848:0.018049:0.012604:0.007466:0.006523:0.009448:0.013143:0.003848:0.003848:0.009448:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009448:0.015990:0.003848:0.006523:0.011738:0.009448:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.009448:0.005713:0.012508:0.011738:0.013143:0.003848:0.005330
cell cancer  (mRCC) are  incurable.  The :@0.084242:0.359811:0.480497:0.359811:0.480497:0.344055:0.084242:0.344055:0.012450:0.012508:0.003848:0.003848:0.011545:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.006196:0.007100:0.018049:0.011680:0.015644:0.015644:0.007100:0.011545:0.013143:0.005715:0.012508:0.005330:0.006204:0.003848:0.011738:0.012450:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.005330:0.005330:0.006204:0.008197:0.011738:0.012508:0.005330
selection of treatment depends on many :@0.084242:0.376202:0.480478:0.376202:0.480478:0.360446:0.084242:0.360446:0.007466:0.012508:0.003848:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.006850:0.012604:0.006042:0.006850:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006850:0.013181:0.012508:0.013123:0.012508:0.011738:0.013181:0.007466:0.006850:0.012604:0.011738:0.006850:0.018049:0.013143:0.011738:0.010314:0.005330
factors, including prior treatment and site :@0.084242:0.392593:0.480486:0.392593:0.480486:0.376837:0.084242:0.376837:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.006696:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.006696:0.013123:0.005792:0.003848:0.012604:0.005792:0.006696:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006687:0.013143:0.011738:0.013181:0.006696:0.007466:0.003848:0.006523:0.012508:0.005330
of recurrence, as well as individual patient :@0.084242:0.408984:0.480465:0.408984:0.480465:0.393228:0.084242:0.393228:0.012604:0.006042:0.005003:0.005713:0.012508:0.012450:0.011699:0.005792:0.005713:0.012508:0.011738:0.012450:0.012508:0.005330:0.004993:0.013143:0.007466:0.005003:0.015990:0.012508:0.003848:0.003848:0.005003:0.013143:0.007466:0.005003:0.003848:0.011738:0.013181:0.003848:0.010660:0.003864:0.013181:0.011699:0.013143:0.003848:0.005003:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330
considerations, such as performance sta-:@0.084242:0.425375:0.475165:0.425375:0.475165:0.409619:0.084242:0.409619:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.006993:0.007466:0.011699:0.012450:0.011738:0.007004:0.013143:0.007466:0.007004:0.013123:0.012508:0.006710:0.006042:0.012604:0.006323:0.018049:0.013143:0.011738:0.012450:0.012508:0.007004:0.007466:0.006523:0.013143:0.006388
tus (PS).:@0.084242:0.441766:0.155766:0.441766:0.155766:0.426010:0.084242:0.426010:0.006523:0.011699:0.007466:0.005330:0.007100:0.011392:0.009583:0.007100:0.005330
Options include surgery, immunotherapy, :@0.102426:0.458157:0.480494:0.458157:0.480494:0.442401:0.102426:0.442401:0.016337:0.012738:0.006138:0.003464:0.012219:0.011353:0.007081:0.006196:0.003464:0.011353:0.012065:0.003464:0.011315:0.012796:0.012123:0.006196:0.007081:0.011315:0.005423:0.012565:0.012123:0.005407:0.009929:0.004945:0.006196:0.003464:0.017665:0.017665:0.011315:0.011353:0.012219:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.009929:0.005326:0.005330
molecular targeted therapy and radiation :@0.084242:0.474548:0.480501:0.474548:0.480501:0.458792:0.084242:0.458792:0.017665:0.012219:0.003464:0.012123:0.012065:0.011315:0.003464:0.012758:0.005407:0.008072:0.006138:0.012758:0.005421:0.012565:0.012123:0.006138:0.012123:0.012796:0.008082:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.009929:0.008072:0.012758:0.011353:0.012796:0.008072:0.005407:0.012758:0.012796:0.003464:0.012758:0.006138:0.003464:0.012219:0.011734:0.005330
for the management of metastatic lesions.:@0.084242:0.490939:0.464684:0.490939:0.464684:0.475183:0.084242:0.475183:0.005657:0.012219:0.005407:0.004945:0.006138:0.011353:0.012123:0.004945:0.017665:0.012758:0.011353:0.012758:0.012565:0.012123:0.017665:0.012123:0.011353:0.006138:0.004945:0.012219:0.005657:0.004945:0.017665:0.012123:0.006138:0.012758:0.007081:0.006138:0.012758:0.006138:0.003464:0.012065:0.004945:0.003464:0.012123:0.007081:0.003464:0.012219:0.011353:0.007081:0.005330
Surgery:@0.084242:0.523986:0.162067:0.523986:0.162067:0.505965:0.084242:0.505965:0.011118:0.012828:0.006842:0.014111:0.013683:0.006842:0.012401
Nephrectomy can aid in the palliation of :@0.084242:0.541518:0.480482:0.541518:0.480482:0.525762:0.084242:0.525762:0.014239:0.012508:0.013123:0.011738:0.005705:0.012508:0.012450:0.006523:0.012604:0.018049:0.010314:0.007158:0.012450:0.013143:0.011738:0.007158:0.013143:0.003848:0.013181:0.007170:0.003848:0.011738:0.007158:0.006523:0.011738:0.012508:0.007158:0.013123:0.013143:0.003848:0.003848:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.007175:0.012604:0.006042:0.005330
symptoms caused by the primary tumour, :@0.084242:0.557909:0.480449:0.557909:0.480449:0.542153:0.084242:0.542153:0.007466:0.010314:0.018049:0.013123:0.006523:0.012604:0.018049:0.007466:0.006581:0.012450:0.013143:0.011699:0.007466:0.012508:0.013181:0.006581:0.013123:0.010314:0.006581:0.006523:0.011738:0.012508:0.006581:0.013123:0.005792:0.003848:0.018049:0.013143:0.005792:0.010314:0.006581:0.006523:0.011699:0.018049:0.012604:0.011699:0.003758:0.005330:0.005330
related ectopic hormone or cytokine pro-:@0.084242:0.574300:0.475173:0.574300:0.475173:0.558544:0.084242:0.558544:0.005713:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.005715:0.012508:0.012450:0.006523:0.012604:0.013123:0.003848:0.012450:0.005715:0.011738:0.012604:0.006315:0.018049:0.012604:0.011738:0.012508:0.005715:0.012604:0.005792:0.005715:0.012450:0.010314:0.006523:0.012604:0.009660:0.003848:0.011738:0.012508:0.005715:0.013123:0.005715:0.012604:0.006388
duction.  Two  randomised  studies  have :@0.084242:0.590691:0.480476:0.590691:0.480476:0.574935:0.084242:0.574935:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330:0.008253:0.008326:0.015990:0.012604:0.005330:0.008259:0.005792:0.013143:0.011738:0.013181:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.005330:0.008263:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.007466:0.005330:0.008265:0.011738:0.013143:0.010660:0.012508:0.005330
demonstrated an overall survival benefit in :@0.084242:0.607082:0.480480:0.607082:0.480480:0.591326:0.084242:0.591326:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.013181:0.004376:0.013143:0.011738:0.004387:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.004391:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.004403:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.004378:0.003848:0.011738:0.005330
selected patients with metastatic disease :@0.084242:0.623473:0.480463:0.623473:0.480463:0.607717:0.084242:0.607717:0.007466:0.012508:0.003848:0.012508:0.012450:0.006523:0.012508:0.013181:0.006658:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006658:0.015990:0.003848:0.006523:0.011738:0.006658:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.006658:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330
who have undergone initial cytoreductive :@0.084242:0.639864:0.480486:0.639864:0.480486:0.624108:0.084242:0.624108:0.015990:0.011738:0.012604:0.005003:0.011738:0.013143:0.010660:0.012508:0.005003:0.011699:0.011738:0.013181:0.012508:0.005807:0.012950:0.012604:0.011738:0.012508:0.005003:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.003848:0.005020:0.012450:0.010314:0.006523:0.012604:0.005705:0.012508:0.013181:0.011699:0.012450:0.006523:0.003848:0.010660:0.012508:0.005330
nephrectomy prior to the administration of :@0.084242:0.656255:0.480494:0.656255:0.480494:0.640499:0.084242:0.640499:0.011738:0.012508:0.013123:0.011738:0.005707:0.012508:0.012450:0.006523:0.012604:0.018049:0.010314:0.004503:0.013123:0.005792:0.003848:0.012604:0.005792:0.004503:0.006523:0.012604:0.004503:0.006523:0.011738:0.012508:0.004503:0.013143:0.013181:0.018049:0.003848:0.011738:0.003848:0.007466:0.006523:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.004503:0.012604:0.006042:0.005330
interferon-alpha (IFN).:@0.084242:0.672646:0.288331:0.672646:0.288331:0.656890:0.084242:0.656890:0.003848:0.011738:0.006523:0.012508:0.006706:0.006042:0.012508:0.005709:0.012604:0.011738:0.006388:0.013143:0.003848:0.013123:0.011738:0.013143:0.005330:0.007100:0.004349:0.009333:0.014239:0.007100:0.005330
2,3:@0.288326:0.666984:0.303864:0.666984:0.303864:0.657799:0.288326:0.657799:0.006215:0.003107:0.006215
Patients with solitary or a limited number :@0.102424:0.688989:0.480495:0.688989:0.480495:0.673233:0.102424:0.673233:0.011199:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.006408:0.015798:0.003656:0.006331:0.011545:0.006408:0.007274:0.012411:0.003656:0.003656:0.006331:0.012950:0.005600:0.010122:0.006408:0.012411:0.005600:0.006408:0.012950:0.006408:0.003656:0.003656:0.017857:0.003656:0.006331:0.012315:0.012989:0.006408:0.011545:0.011507:0.017857:0.012931:0.012315:0.005788:0.005330
of distant metastases can achieve prolong- :@0.084240:0.705380:0.480480:0.705380:0.480480:0.689624:0.084240:0.689624:0.012411:0.005850:0.003772:0.012989:0.003656:0.007274:0.006331:0.012950:0.011545:0.006331:0.003772:0.017857:0.012315:0.006331:0.012950:0.007274:0.006331:0.012950:0.007274:0.012315:0.007274:0.003772:0.012257:0.012950:0.011545:0.003772:0.012950:0.012257:0.011545:0.003656:0.012315:0.010468:0.012315:0.003772:0.012931:0.005521:0.012411:0.003656:0.012411:0.011545:0.012758:0.006352:0.005330
ed survival with nephrectomy and surgical :@0.084240:0.721771:0.480495:0.721771:0.480495:0.706015:0.084240:0.706015:0.012315:0.012989:0.006042:0.007274:0.011507:0.005600:0.010468:0.003656:0.010468:0.012950:0.003656:0.006042:0.015798:0.003656:0.006331:0.011545:0.006042:0.011545:0.012315:0.012931:0.011545:0.005521:0.012315:0.012257:0.006331:0.012411:0.017857:0.010122:0.006042:0.012950:0.011545:0.012989:0.006042:0.007274:0.011507:0.005615:0.012758:0.003656:0.012257:0.012950:0.003850:0.005330
resection  of  the  metastases.  This  is  more :@0.084240:0.738162:0.480491:0.738162:0.480491:0.722406:0.084240:0.722406:0.005521:0.012315:0.007274:0.012315:0.012257:0.006331:0.003656:0.012411:0.011545:0.005330:0.004859:0.012411:0.005850:0.005330:0.004859:0.006331:0.011545:0.012315:0.005330:0.004859:0.017857:0.012315:0.006331:0.012950:0.007274:0.006331:0.012950:0.007274:0.012315:0.007274:0.005138:0.005330:0.004859:0.008005:0.011545:0.003656:0.007274:0.005330:0.004859:0.003656:0.007274:0.005330:0.004859:0.017857:0.012411:0.005519:0.012506:0.005330
likely in patients  with  a long disease-free :@0.084240:0.754553:0.480495:0.754553:0.480495:0.738797:0.084240:0.738797:0.003656:0.003656:0.009467:0.012315:0.003656:0.010122:0.009621:0.003656:0.011545:0.009621:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.005330:0.004281:0.015798:0.003656:0.006331:0.011545:0.005330:0.004281:0.012950:0.009621:0.003656:0.012411:0.011545:0.012758:0.009621:0.012989:0.003656:0.007274:0.012315:0.012950:0.007274:0.012315:0.006196:0.005850:0.005521:0.012315:0.012506:0.005330
interval between the initial nephrectomy :@0.084240:0.770944:0.480499:0.770944:0.480499:0.755188:0.084240:0.755188:0.003656:0.011545:0.006331:0.012315:0.005600:0.010468:0.012950:0.003656:0.009968:0.012931:0.012315:0.006331:0.015798:0.012315:0.012315:0.011545:0.009968:0.006331:0.011545:0.012315:0.009968:0.003656:0.011545:0.003656:0.006331:0.003656:0.012950:0.003656:0.009968:0.011545:0.012315:0.012931:0.011545:0.005521:0.012315:0.012257:0.006331:0.012411:0.017857:0.010316:0.005330
and the development of metastases.:@0.084240:0.787335:0.424061:0.787335:0.424061:0.771579:0.084240:0.771579:0.012950:0.011545:0.012989:0.005138:0.006331:0.011545:0.012315:0.005138:0.012989:0.012315:0.010468:0.012315:0.003656:0.012411:0.012931:0.017857:0.012315:0.011545:0.006331:0.005138:0.012411:0.005850:0.005138:0.017857:0.012315:0.006331:0.012950:0.007274:0.006331:0.012950:0.007274:0.012315:0.007274:0.005330
Cytokine therapy:@0.084242:0.820398:0.263838:0.820398:0.263838:0.802377:0.084242:0.802377:0.016677:0.012401:0.006414:0.013683:0.012401:0.005131:0.012828:0.013683:0.005987:0.006414:0.012828:0.013683:0.006842:0.014111:0.014111:0.012401
Cytokine  therapy represents the  early :@0.084242:0.837930:0.480494:0.837930:0.480494:0.822174:0.084242:0.822174:0.015644:0.010314:0.006523:0.012604:0.009660:0.003848:0.011738:0.012508:0.005330:0.010491:0.006523:0.011738:0.012508:0.005792:0.013133:0.013123:0.010314:0.015836:0.005713:0.012508:0.013123:0.005713:0.012508:0.007466:0.012508:0.011738:0.006523:0.007466:0.015836:0.006523:0.011738:0.012508:0.005330:0.010489:0.012508:0.013143:0.005792:0.003848:0.010314:0.005330
days in immunotherapy.  Although  there :@0.084242:0.854321:0.480495:0.854321:0.480495:0.838565:0.084242:0.838565:0.013181:0.013143:0.010314:0.007466:0.010622:0.003848:0.011738:0.010622:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.005274:0.014239:0.003848:0.006523:0.011738:0.012604:0.011699:0.012950:0.011738:0.005330:0.005274:0.006523:0.011738:0.012508:0.005705:0.012508:0.005330
are data from the mid-1990s to substanti-:@0.084242:0.870712:0.475148:0.870712:0.475148:0.854956:0.084242:0.854956:0.013143:0.005715:0.012508:0.006954:0.013181:0.013143:0.006523:0.013143:0.006966:0.006042:0.005711:0.012604:0.018049:0.006952:0.006523:0.011738:0.012508:0.006950:0.018049:0.003848:0.013181:0.006388:0.010660:0.010660:0.010660:0.010660:0.007466:0.006983:0.006523:0.012604:0.006950:0.007466:0.011699:0.013123:0.007466:0.006523:0.013143:0.011738:0.006523:0.003848:0.006388
ate the use of interleukin-2 (IL-2), it has not :@0.084242:0.887103:0.480509:0.887103:0.480509:0.871347:0.084242:0.871347:0.013143:0.006523:0.012508:0.005436:0.006523:0.011738:0.012508:0.005430:0.011699:0.007466:0.012508:0.005446:0.012604:0.006042:0.005434:0.003848:0.011738:0.006523:0.012508:0.005792:0.003848:0.012508:0.011699:0.009660:0.003848:0.011738:0.006388:0.010660:0.005432:0.007100:0.004349:0.008890:0.006388:0.010660:0.007100:0.005330:0.005446:0.003848:0.006523:0.005446:0.011738:0.013143:0.007466:0.005446:0.011738:0.012604:0.006523:0.005330
been compared to the new-generation :@0.084242:0.903494:0.480499:0.903494:0.480499:0.887738:0.084242:0.887738:0.013123:0.012508:0.012508:0.011738:0.010102:0.012450:0.012604:0.018049:0.013123:0.013143:0.005713:0.012508:0.013181:0.010102:0.006523:0.012604:0.010102:0.006523:0.011738:0.012508:0.010102:0.011738:0.012508:0.015990:0.006388:0.012950:0.012508:0.011738:0.012508:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
checkpoint  inhibitor and is generally not :@0.084242:0.919884:0.480505:0.919884:0.480505:0.904129:0.084242:0.904129:0.012450:0.011738:0.012508:0.012450:0.009660:0.013123:0.012604:0.003848:0.011738:0.006523:0.005330:0.003525:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.008871:0.013143:0.011738:0.013181:0.008871:0.003848:0.007466:0.008871:0.012950:0.012508:0.011738:0.012508:0.005792:0.013143:0.003848:0.003848:0.010314:0.008871:0.011738:0.012604:0.006523:0.005330
offered any more.:@0.084242:0.936275:0.252937:0.936275:0.252937:0.920519:0.084242:0.920519:0.012604:0.006094:0.006042:0.012508:0.005709:0.012508:0.013181:0.005330:0.013143:0.011738:0.010314:0.005330:0.018049:0.012604:0.005703:0.012508:0.005330
TARGETED THERAPIES AND :@0.523636:0.096122:0.792602:0.096122:0.792602:0.078306:0.523636:0.078306:0.008980:0.015822:0.012401:0.017960:0.011118:0.008980:0.011118:0.014966:0.005987:0.008980:0.014539:0.011118:0.012401:0.015822:0.011973:0.005987:0.011118:0.011118:0.005987:0.015822:0.015822:0.014966:0.005987
CHECKPOINT INHIBITORS:@0.523636:0.113981:0.773787:0.113981:0.773787:0.096166:0.523636:0.096166:0.016677:0.014539:0.011118:0.016677:0.013256:0.011973:0.017960:0.005987:0.015822:0.008980:0.005987:0.005987:0.015822:0.014539:0.005987:0.012401:0.005987:0.008980:0.017960:0.012401:0.011118
A growing understanding of the biology of :@0.523636:0.131524:0.919908:0.131524:0.919908:0.115768:0.523636:0.115768:0.014239:0.004676:0.012950:0.005709:0.012604:0.015990:0.003848:0.011738:0.012950:0.004676:0.011699:0.011738:0.013181:0.012508:0.005792:0.007466:0.006523:0.013143:0.011738:0.013181:0.003848:0.011738:0.012950:0.004676:0.012604:0.006042:0.004676:0.006523:0.011738:0.012508:0.004676:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.010314:0.004676:0.012604:0.006042:0.005330
RCC has led to the development and reg-:@0.523636:0.147915:0.914524:0.147915:0.914524:0.132159:0.523636:0.132159:0.011680:0.015644:0.015644:0.004753:0.011738:0.013143:0.007466:0.004753:0.003848:0.012508:0.013181:0.004753:0.006523:0.012604:0.004753:0.006523:0.011738:0.012508:0.004753:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.018049:0.012508:0.011738:0.006523:0.004753:0.013143:0.011738:0.013181:0.004753:0.005713:0.012508:0.012950:0.006388
istration of several targeted therapies and :@0.523636:0.164306:0.919885:0.164306:0.919885:0.148550:0.523636:0.148550:0.003848:0.007466:0.006523:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005407:0.012604:0.006042:0.005397:0.007466:0.012508:0.010660:0.012508:0.005792:0.013143:0.003848:0.005407:0.006523:0.013143:0.005805:0.012950:0.012508:0.006523:0.012508:0.013181:0.005394:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.007466:0.005407:0.013143:0.011738:0.013181:0.005330
immune checkpoint inhibitors.:@0.523636:0.180697:0.802689:0.180697:0.802689:0.164941:0.523636:0.164941:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508:0.005330:0.012450:0.011738:0.012508:0.012450:0.009660:0.013123:0.012604:0.003848:0.011738:0.006523:0.005330:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.005330
Targeted agents either block the mam-:@0.541820:0.197088:0.914551:0.197088:0.914551:0.181332:0.541820:0.181332:0.007197:0.013143:0.005809:0.012950:0.012508:0.006523:0.012508:0.013181:0.006714:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.006723:0.012508:0.003848:0.006523:0.011738:0.012508:0.005792:0.006712:0.013123:0.003848:0.012604:0.012450:0.009660:0.006721:0.006523:0.011738:0.012508:0.006716:0.018049:0.013143:0.018049:0.006388
malian target of rapamycin (mTOR), while :@0.523636:0.213478:0.919872:0.213478:0.919872:0.197723:0.523636:0.197723:0.018049:0.013143:0.003848:0.003848:0.013143:0.011738:0.005465:0.006523:0.013143:0.005807:0.012950:0.012508:0.006523:0.005465:0.012604:0.006042:0.005465:0.005792:0.013143:0.013123:0.013143:0.018049:0.010314:0.012450:0.003848:0.011738:0.005465:0.007100:0.018049:0.008197:0.016722:0.011680:0.007100:0.005330:0.005465:0.015990:0.011738:0.003848:0.003848:0.012508:0.005330
a number  of  agents  target  the  vascular :@0.523636:0.229869:0.919875:0.229869:0.919875:0.214113:0.523636:0.214113:0.013143:0.009256:0.011738:0.011699:0.018049:0.013123:0.012508:0.005792:0.005330:0.003910:0.012604:0.006042:0.005330:0.003912:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330:0.003910:0.006523:0.013143:0.005807:0.012950:0.012508:0.006523:0.005330:0.003910:0.006523:0.011738:0.012508:0.005330:0.003912:0.010660:0.013143:0.007466:0.012450:0.011699:0.003848:0.013143:0.005792:0.005330
endothelial growth  factor  (VEGF) path-:@0.523636:0.246260:0.914555:0.246260:0.914555:0.230504:0.523636:0.230504:0.012508:0.011738:0.013181:0.012604:0.006523:0.011738:0.012508:0.003848:0.003848:0.013143:0.003848:0.012084:0.012950:0.005711:0.012604:0.015990:0.006523:0.011738:0.005330:0.006744:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.005330:0.006739:0.007100:0.013508:0.010314:0.016779:0.009333:0.007100:0.012084:0.013123:0.013143:0.006523:0.011738:0.006388
way through tyrosine kinase inhibitors (TKIs) :@0.523636:0.262651:0.919858:0.262651:0.919858:0.246895:0.523636:0.246895:0.015990:0.013143:0.010314:0.004668:0.006523:0.011738:0.005707:0.012604:0.011699:0.012950:0.011738:0.004657:0.006523:0.010314:0.005713:0.012604:0.007466:0.003848:0.011738:0.012508:0.004657:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.004657:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.004657:0.007100:0.008197:0.011372:0.004349:0.007466:0.007100:0.005330
or monoclonal antibodies (MAB).:@0.523636:0.279042:0.831130:0.279042:0.831130:0.263286:0.523636:0.263286:0.012604:0.005792:0.005330:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.003848:0.012508:0.007466:0.005330:0.007100:0.017684:0.014239:0.011045:0.007100:0.005330
Checkpoint  inhibitors block the  pro-:@0.541820:0.295433:0.914559:0.295433:0.914559:0.279677:0.541820:0.279677:0.015644:0.011738:0.012508:0.012450:0.009660:0.013123:0.012604:0.003848:0.011738:0.006523:0.005330:0.010185:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.015529:0.013123:0.003848:0.012604:0.012450:0.009660:0.015529:0.006523:0.011738:0.012508:0.005330:0.010187:0.013123:0.005715:0.012604:0.006388
grammed cell-death protein or ligand (PD :@0.523636:0.311824:0.919879:0.311824:0.919879:0.296068:0.523636:0.296068:0.012950:0.005792:0.013143:0.018049:0.018049:0.012508:0.013181:0.005022:0.012450:0.012508:0.003848:0.003848:0.006388:0.013181:0.012508:0.013143:0.006523:0.011738:0.005024:0.013123:0.005715:0.012604:0.006523:0.012508:0.003848:0.011738:0.005022:0.012604:0.005792:0.005024:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.005042:0.007100:0.011392:0.014316:0.005330
or PD-L) through monoclonal antibodies.:@0.523636:0.328215:0.900323:0.328215:0.900323:0.312459:0.523636:0.312459:0.012604:0.005792:0.005330:0.011392:0.014316:0.006388:0.008890:0.007100:0.005330:0.006523:0.011738:0.005694:0.012604:0.011699:0.012950:0.011738:0.005330:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.003848:0.012508:0.007466:0.005330
mTOR target inhibitors:@0.523636:0.361347:0.748131:0.361347:0.748131:0.343326:0.523636:0.343326:0.020098:0.008980:0.017960:0.012401:0.005987:0.006414:0.014111:0.006842:0.014111:0.013683:0.006414:0.005987:0.005131:0.012828:0.012828:0.005131:0.014111:0.005131:0.006414:0.013683:0.006842:0.009407
Two mTOR inhibitors, temsirolimus and everoli-:@0.523636:0.378887:0.914540:0.378887:0.914540:0.363131:0.523636:0.363131:0.007747:0.015413:0.012027:0.003760:0.017472:0.007620:0.016144:0.011103:0.003760:0.003271:0.011161:0.011161:0.003271:0.012546:0.003271:0.005946:0.012027:0.005215:0.006889:0.004753:0.003762:0.005946:0.011930:0.017472:0.006889:0.003271:0.005136:0.012027:0.003271:0.003271:0.017472:0.011122:0.006889:0.003762:0.012565:0.011161:0.012604:0.003762:0.011930:0.010083:0.011930:0.005136:0.012027:0.003271:0.003271:0.006388
mus, have shown clinical activity in RCC.:@0.523636:0.395277:0.879024:0.395277:0.879024:0.379522:0.523636:0.379522:0.017472:0.011122:0.006889:0.004753:0.004753:0.011161:0.012565:0.010083:0.011930:0.004753:0.006889:0.011161:0.012027:0.015413:0.011161:0.004753:0.011873:0.003271:0.003271:0.011161:0.003271:0.011873:0.012565:0.003271:0.004753:0.012565:0.011873:0.005946:0.003271:0.010083:0.003271:0.005946:0.009737:0.004753:0.003271:0.011161:0.004753:0.011103:0.015067:0.015067:0.005330
Temsirolimus, an intravenously-adminis-:@0.541820:0.411668:0.914545:0.411668:0.914545:0.395912:0.541820:0.395912:0.007254:0.012508:0.018049:0.007466:0.003848:0.005717:0.012604:0.003848:0.003848:0.018049:0.011699:0.007466:0.005330:0.012103:0.013143:0.011738:0.012103:0.003848:0.011738:0.006523:0.005792:0.013143:0.010660:0.012508:0.011738:0.012604:0.011699:0.007466:0.003848:0.010314:0.006388:0.013143:0.013181:0.018049:0.003848:0.011738:0.003848:0.007483:0.006388
tered  mTOR  inhibitor,  has  resulted  in  pro-:@0.523636:0.428059:0.914549:0.428059:0.914549:0.412303:0.523636:0.412303:0.006523:0.012508:0.005707:0.012508:0.013181:0.005330:0.003046:0.018049:0.008197:0.016722:0.011680:0.005330:0.003044:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.003770:0.005330:0.005330:0.003042:0.011738:0.013143:0.007466:0.005330:0.003050:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.012508:0.013181:0.005330:0.003046:0.003848:0.011738:0.005330:0.003048:0.013123:0.005715:0.012604:0.006388
longed overall survival  (OS) compared :@0.523636:0.444450:0.919868:0.444450:0.919868:0.428694:0.523636:0.428694:0.003848:0.012604:0.011738:0.012950:0.012508:0.013181:0.013316:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.013316:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.008001:0.007100:0.016722:0.009583:0.007100:0.013316:0.012450:0.012604:0.018049:0.013123:0.013143:0.005711:0.012508:0.013181:0.005330
with IFN in a phase III randomised con-:@0.523636:0.460841:0.914536:0.460841:0.914536:0.445085:0.523636:0.445085:0.015990:0.003848:0.006523:0.011738:0.010064:0.004349:0.009333:0.014239:0.010064:0.003848:0.011738:0.010064:0.013143:0.010064:0.013123:0.011738:0.013143:0.007466:0.012508:0.010064:0.004349:0.004349:0.004349:0.010064:0.005792:0.013143:0.011738:0.013181:0.012594:0.018049:0.003848:0.007466:0.012508:0.013181:0.010064:0.012450:0.012604:0.011738:0.006388
trolled trial that enrolled intermediate- :@0.523636:0.477232:0.919872:0.477232:0.919872:0.461476:0.523636:0.461476:0.006523:0.005709:0.012604:0.003848:0.003848:0.012508:0.013181:0.014643:0.006523:0.005792:0.003848:0.013143:0.003848:0.014643:0.006523:0.011738:0.013143:0.006523:0.014643:0.012508:0.011738:0.005709:0.012604:0.003848:0.003848:0.012508:0.013181:0.014643:0.003848:0.011738:0.006523:0.012508:0.006319:0.018049:0.012508:0.013181:0.003848:0.013143:0.006523:0.012508:0.006388:0.005330
and poor-risk  patients. The  hazard ratio :@0.523636:0.493623:0.919893:0.493623:0.919893:0.477867:0.523636:0.477867:0.013143:0.011738:0.013181:0.011199:0.013123:0.012604:0.012604:0.005792:0.006388:0.005792:0.003848:0.007466:0.009660:0.005330:0.005859:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.011199:0.008197:0.011738:0.012508:0.005330:0.005857:0.011738:0.013143:0.008178:0.013143:0.005677:0.013181:0.011199:0.005792:0.013143:0.006523:0.003848:0.012604:0.005330
(HR) for death was 0.73 (95% CI, 0.58-0.92, :@0.523636:0.510014:0.919870:0.510014:0.919870:0.494258:0.523636:0.494258:0.007100:0.013143:0.011680:0.007100:0.005927:0.006042:0.012604:0.005782:0.005917:0.013181:0.012508:0.013143:0.006523:0.011738:0.005913:0.015990:0.013143:0.007466:0.005927:0.010660:0.005330:0.010660:0.010660:0.005927:0.007100:0.010660:0.010660:0.014913:0.005927:0.015644:0.004349:0.005330:0.005915:0.010660:0.005330:0.010660:0.010660:0.006388:0.010660:0.005330:0.010660:0.010660:0.005330:0.005330
p = 0.008).:@0.523636:0.526405:0.619482:0.526405:0.619482:0.510649:0.523636:0.510649:0.013123:0.005330:0.011661:0.005330:0.010660:0.005330:0.010660:0.010660:0.010660:0.007100:0.005330
4:@0.619491:0.520803:0.625706:0.520803:0.625706:0.511618:0.619491:0.511618:0.006215
Everolimus is an  orally administered :@0.541818:0.542815:0.919885:0.542815:0.919885:0.527059:0.541818:0.527059:0.010314:0.010660:0.012508:0.005717:0.012604:0.003848:0.003848:0.018049:0.011699:0.007466:0.017145:0.003848:0.007466:0.017145:0.013143:0.011738:0.005330:0.011805:0.012604:0.005792:0.013143:0.003848:0.003848:0.010314:0.017145:0.013143:0.013181:0.018049:0.003848:0.011738:0.003848:0.007466:0.006523:0.012508:0.005715:0.012508:0.013181:0.005330
mTOR inhibitor that was  evaluated in a :@0.523634:0.559206:0.919846:0.559206:0.919846:0.543450:0.523634:0.543450:0.018049:0.008197:0.016722:0.011680:0.010449:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.010449:0.006523:0.011738:0.013143:0.006523:0.010449:0.015990:0.013143:0.007466:0.005330:0.005130:0.012508:0.010660:0.013143:0.003848:0.011699:0.013143:0.006523:0.012508:0.013181:0.010449:0.003848:0.011738:0.010449:0.013143:0.005330
second-line phase III trial in patients with :@0.523634:0.575597:0.919854:0.575597:0.919854:0.559841:0.523634:0.559841:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.006388:0.003848:0.003848:0.011738:0.012508:0.008313:0.013123:0.011738:0.013143:0.007466:0.012508:0.008313:0.004349:0.004349:0.004349:0.008313:0.006523:0.005792:0.003848:0.013143:0.003848:0.008313:0.003848:0.011738:0.008313:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008313:0.015990:0.003848:0.006523:0.011738:0.005330
metastatic RCC with a clear-cell compo-:@0.523634:0.591988:0.914562:0.591988:0.914562:0.576232:0.523634:0.576232:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.006908:0.011680:0.015644:0.015644:0.006908:0.015990:0.003848:0.006523:0.011738:0.006908:0.013143:0.006908:0.012450:0.003848:0.012508:0.013143:0.005792:0.006388:0.012450:0.012508:0.003848:0.003848:0.006908:0.012450:0.012604:0.018049:0.013123:0.012604:0.006388
nent that had progressed during or within :@0.523634:0.608379:0.919887:0.608379:0.919887:0.592623:0.523634:0.592623:0.011738:0.012508:0.011738:0.006523:0.006312:0.006523:0.011738:0.013143:0.006523:0.006317:0.011738:0.013143:0.013181:0.006321:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.006331:0.013181:0.011699:0.005792:0.003848:0.011738:0.012950:0.006319:0.012604:0.005792:0.006312:0.015990:0.003848:0.006523:0.011738:0.003848:0.011738:0.005330
six months of stopping treatment with suni-:@0.523634:0.624770:0.914568:0.624770:0.914568:0.609014:0.523634:0.609014:0.007466:0.003848:0.009236:0.004965:0.018049:0.012604:0.011738:0.006514:0.011738:0.007466:0.004965:0.012604:0.006042:0.004965:0.007466:0.006523:0.012604:0.013123:0.013123:0.003848:0.011738:0.012950:0.004965:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004965:0.015990:0.003848:0.006523:0.011738:0.004965:0.007466:0.011699:0.011738:0.003848:0.006388
tinib or sorafenib.:@0.523634:0.641161:0.683365:0.641161:0.683365:0.625405:0.523634:0.625405:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330:0.012604:0.005792:0.005330:0.007466:0.012604:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.005330
5:@0.683353:0.635553:0.689568:0.635553:0.689568:0.626368:0.683353:0.626368:0.006215
Based on these results, everolimus is indi- :@0.541818:0.657565:0.919854:0.657565:0.919854:0.641809:0.541818:0.641809:0.011045:0.013143:0.007466:0.012508:0.013181:0.005093:0.012604:0.011738:0.005080:0.006523:0.011738:0.012508:0.007466:0.012508:0.005080:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.005330:0.005080:0.012508:0.010660:0.012508:0.005711:0.012604:0.003848:0.003848:0.018049:0.011699:0.007466:0.005080:0.003848:0.007466:0.005092:0.003848:0.011738:0.013181:0.003848:0.006388:0.005330
cated for patients with metastatic clear-:@0.523634:0.673956:0.914524:0.673956:0.914524:0.658200:0.523634:0.658200:0.012450:0.013143:0.006523:0.012508:0.013181:0.008274:0.006042:0.012604:0.005792:0.008274:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008274:0.015990:0.003848:0.006523:0.011738:0.008274:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.008274:0.012450:0.003848:0.012508:0.013143:0.005792:0.006388
cell RCC who have progressed on previ-:@0.523634:0.690347:0.914535:0.690347:0.914535:0.674591:0.523634:0.674591:0.012450:0.012508:0.003848:0.003848:0.007851:0.011680:0.015644:0.015644:0.007851:0.015990:0.011738:0.012604:0.007841:0.011738:0.013143:0.010660:0.012508:0.007851:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.007851:0.012604:0.011738:0.007841:0.013123:0.005717:0.012508:0.010660:0.003848:0.006388
ous vascular endothelial growth  factor :@0.523634:0.706738:0.919892:0.706738:0.919892:0.690982:0.523634:0.690982:0.012604:0.011699:0.007466:0.013354:0.010660:0.013143:0.007466:0.012450:0.011699:0.003848:0.013143:0.005792:0.013354:0.012508:0.011738:0.013181:0.012604:0.006523:0.011738:0.012508:0.003848:0.003848:0.013143:0.003848:0.013354:0.012950:0.005711:0.012604:0.015990:0.006523:0.011738:0.005330:0.008009:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.005330
(VEGF) tyrosine  kinase inhibitors  (TKIs), :@0.523634:0.723129:0.919881:0.723129:0.919881:0.707373:0.523634:0.707373:0.007100:0.013508:0.010314:0.016779:0.009333:0.007100:0.016529:0.006523:0.010314:0.005713:0.012604:0.007466:0.003848:0.011738:0.012508:0.005330:0.011186:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.016699:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.005330:0.011188:0.007100:0.008197:0.011372:0.004349:0.007466:0.007100:0.005330:0.005330
 :@0.749890:0.723129:0.755277:0.723129:0.755277:0.707095:0.749890:0.707095:0.005388
while temsirolimus is indicated for poor-risk :@0.523634:0.739520:0.919867:0.739520:0.919867:0.723764:0.523634:0.723764:0.015990:0.011738:0.003848:0.003848:0.012508:0.005580:0.006523:0.012508:0.018049:0.007466:0.003848:0.005721:0.012604:0.003848:0.003848:0.018049:0.011699:0.007466:0.005580:0.003848:0.007466:0.005580:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005580:0.006042:0.012604:0.005792:0.005569:0.013123:0.012604:0.012604:0.005792:0.006388:0.005792:0.003848:0.007466:0.009660:0.005330
disease. Although the benefit associated :@0.523634:0.755911:0.919873:0.755911:0.919873:0.740155:0.523634:0.740155:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.007824:0.014239:0.003848:0.006523:0.011738:0.012604:0.011688:0.012950:0.011738:0.007812:0.006523:0.011738:0.012508:0.007810:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.007814:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330
with everolimus is significant in comparison :@0.523634:0.772302:0.919871:0.772302:0.919871:0.756546:0.523634:0.756546:0.015990:0.003848:0.006523:0.011738:0.004620:0.012508:0.010660:0.012508:0.005713:0.012604:0.003848:0.003848:0.018049:0.011699:0.007466:0.004620:0.003848:0.007466:0.004628:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.004620:0.003848:0.011738:0.004622:0.012450:0.012604:0.018049:0.013123:0.013143:0.005792:0.003848:0.007466:0.012604:0.011738:0.005330
to placebo, its value relative to other TKIs :@0.523634:0.788693:0.919875:0.788693:0.919875:0.772937:0.523634:0.772937:0.006523:0.012604:0.006793:0.013123:0.003848:0.013143:0.012450:0.012508:0.013123:0.012604:0.005330:0.006793:0.003848:0.006523:0.007466:0.006793:0.010660:0.013143:0.003848:0.011699:0.012508:0.006793:0.005713:0.012508:0.003848:0.013143:0.006523:0.003848:0.010660:0.012508:0.006793:0.006523:0.012604:0.006793:0.012604:0.006523:0.011738:0.012508:0.005792:0.006777:0.008197:0.011372:0.004349:0.007466:0.005330
remains to be determined.:@0.523634:0.805084:0.772528:0.805084:0.772528:0.789328:0.523634:0.789328:0.005713:0.012508:0.018049:0.013143:0.003848:0.011738:0.007466:0.005330:0.006523:0.012604:0.005330:0.013123:0.012508:0.005330:0.013181:0.012508:0.006523:0.012508:0.006308:0.018049:0.003848:0.011738:0.012508:0.013181:0.005330
The  most frequent  side effects of the :@0.541818:0.821474:0.919885:0.821474:0.919885:0.805719:0.541818:0.805719:0.008197:0.011738:0.012508:0.005330:0.005628:0.018049:0.012604:0.007466:0.006523:0.010968:0.006042:0.005713:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.005330:0.005628:0.007466:0.003848:0.013181:0.012508:0.010968:0.012508:0.006094:0.006042:0.012508:0.012450:0.006523:0.007466:0.010968:0.012604:0.006042:0.010968:0.006523:0.011738:0.012508:0.005330
mTOR inhibitors were asthenia, rash, :@0.523634:0.837865:0.919889:0.837865:0.919889:0.822109:0.523634:0.822109:0.018049:0.008197:0.016722:0.011680:0.020031:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.020031:0.015990:0.012508:0.005711:0.012508:0.020031:0.013143:0.007466:0.006523:0.011738:0.012508:0.011738:0.003848:0.013143:0.005330:0.020031:0.005792:0.013143:0.007466:0.011738:0.005330:0.005330
anaemia, lymphopaenia, nausea, and :@0.523634:0.854256:0.919854:0.854256:0.919854:0.838500:0.523634:0.838500:0.013143:0.011738:0.013143:0.012508:0.018049:0.003848:0.013143:0.005330:0.014797:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.014797:0.011738:0.013143:0.011699:0.007466:0.012508:0.013143:0.005330:0.014797:0.013143:0.011738:0.013181:0.005330
anorexia. Severe adverse events were un-:@0.523634:0.870647:0.914555:0.870647:0.914555:0.854891:0.523634:0.854891:0.013143:0.011738:0.012604:0.005707:0.012508:0.009236:0.003848:0.013143:0.005330:0.005397:0.009583:0.012508:0.010660:0.012508:0.005713:0.012508:0.005392:0.013143:0.013181:0.010660:0.012508:0.005792:0.007466:0.012508:0.005407:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.005394:0.015990:0.012508:0.005711:0.012508:0.005394:0.011699:0.011738:0.006388
common; the most frequent grade 3 or 4 :@0.523634:0.887038:0.919877:0.887038:0.919877:0.871282:0.523634:0.871282:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.005330:0.006781:0.006523:0.011738:0.012508:0.006793:0.018049:0.012604:0.007466:0.006523:0.006793:0.006042:0.005711:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.006793:0.012950:0.005792:0.013143:0.013181:0.012508:0.006793:0.010660:0.006793:0.012604:0.005792:0.006793:0.010660:0.005330
adverse events were anaemia, asthenia, :@0.523634:0.903429:0.919850:0.903429:0.919850:0.887673:0.523634:0.887673:0.013143:0.013181:0.010660:0.012508:0.005792:0.007466:0.012508:0.007793:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.007793:0.015990:0.012508:0.005711:0.012508:0.007793:0.013143:0.011738:0.013143:0.012508:0.018049:0.003848:0.013143:0.005330:0.007793:0.013143:0.007466:0.006523:0.011738:0.012508:0.011738:0.003848:0.013143:0.005330:0.005330
hyperglycaemia and pneumonitis. Hyper-:@0.523634:0.919820:0.914533:0.919820:0.914533:0.904064:0.523634:0.904064:0.011738:0.010314:0.013123:0.012508:0.005807:0.012950:0.003848:0.010314:0.012450:0.013143:0.012508:0.018049:0.003848:0.013143:0.006460:0.013143:0.011738:0.013181:0.006446:0.013123:0.011738:0.012508:0.011699:0.018049:0.012604:0.011738:0.003848:0.006523:0.003848:0.007466:0.005330:0.006446:0.013143:0.010314:0.013123:0.012508:0.005792:0.006388
sensitivity reactions  have been  reported :@0.523634:0.936211:0.919885:0.936211:0.919885:0.920455:0.523634:0.920455:0.007466:0.012508:0.011738:0.007466:0.003848:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.010083:0.005711:0.012508:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.004743:0.011738:0.013143:0.010660:0.012508:0.010083:0.013123:0.012508:0.012508:0.011738:0.005330:0.004741:0.005713:0.012508:0.013123:0.012604:0.005792:0.006523:0.012508:0.013181:0.005330